Payment overview · 2025
General Payments
$2,466.92
49 reported records · 13 companies
Healthcare provider profile · identity verified
Georges Junior Joseph, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · WEEKI WACHEE, FL · NPI 1548555956
Verified facts
What the public records show
CMS Open Payments records show Georges Junior Joseph, M.D. received $2,466.92 in general payments during 2025 across 49 reported records.
Abbott Laboratories accounted for 21.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 371 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 371 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $530.05 | 21.5% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $523.13 | 21.2% | 22 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $406.02 | 16.5% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$389.25 | 15.8% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $149.75 | 6.1% | 2 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $135.60 | 5.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $106.18 | 4.3% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $51.40 | 2.1% | 4 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $48.91 | 2.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $46.32 | 1.9% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $32.04 | 1.3% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $30.81 | 1.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.46 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,466.92 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $312.84 | 2 | 2025 |
Source payment records
|
|||||
| LUX-Dx Insertable Cardiac Monitor Normalized: lux dx insertable cardiac monitor |
Device | Boston Scientific Corporation | $249.81 | 4 | 2025 |
Source payment records
|
|||||
| NAVITOR Normalized: navitor |
Device | Abbott Laboratories | $198.36 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $188.26 | 2 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $185.71 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $149.75 | 2 | 2025 |
Source payment records
|
|||||
| EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX Normalized: epi sense guided coagulation system with visitrax |
Device | AtriCure, Inc. | $135.60 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $106.18 | 1 | 2025 |
Source payment records
|
|||||
| General - Brady Normalized: general brady |
Device | Boston Scientific Corporation | $85.62 | 4 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $67.13 | 4 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $51.40 | 4 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP XL VVCS 10-12F Normalized: cardiva vascade mvp xl vvcs 10 12f |
Device | CARDIVA MEDICAL, INC. | $48.91 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $46.32 | 2 | 2025 |
Source payment records
|
|||||
| General - Balloon Catheters Normalized: general balloon catheters |
Device | Boston Scientific Corporation | $33.05 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $32.04 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $30.81 | 1 | 2025 |
Source payment records
|
|||||
| Wolverine Coronary Cutting Balloon Normalized: wolverine coronary cutting balloon |
Device | Boston Scientific Corporation | $24.53 | 1 | 2025 |
Source payment records
|
|||||
| MITRACLIP Normalized: mitraclip |
Device | Abbott Laboratories | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| RESONATE EL ICD VR Normalized: resonate el icd vr |
Device | Boston Scientific Corporation | $18.23 | 3 | 2025 |
Source payment records
|
|||||
| INGEVITY MRI Normalized: ingevity mri |
Device | Boston Scientific Corporation | $17.91 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| LINQ II Normalized: linq ii |
Device | Medtronic, Inc. | $15.28 | 2 | 2025 |
Source payment records
|
|||||
| General - Tachy Normalized: general tachy |
Device | Boston Scientific Corporation | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| ACCOLADE SR Normalized: accolade sr |
Device | Boston Scientific Corporation | $12.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 371 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
371 | 136 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
371 | 136 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 1004 | 352 |
| Clopidogrel | Clopidogrel Bisulfate | 534 | 191 |
| Amlodipine Besylate | Amlodipine Besylate | 421 | 169 |
| Losartan Potassium | Losartan Potassium | 385 | 124 |
| Eliquis | Apixaban | 371 | 136 |
| Carvedilol | Carvedilol | 321 | 109 |
| Atorvastatin Calcium | Atorvastatin Calcium | 307 | 111 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 263 | 94 |
| Furosemide | Furosemide | 254 | 109 |
| Lisinopril | Lisinopril | 250 | 86 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 192 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 181 | 60 |
| Nitroglycerin | Nitroglycerin | 148 | 78 |
| Potassium Chloride | Potassium Chloride | 127 | 56 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 118 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 113 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 108 | 42 |
| Ezetimibe | Ezetimibe | 94 | 36 |
| Xarelto | Rivaroxaban | 94 | 34 |
| Spironolactone | Spironolactone | 68 | 26 |
| Amiodarone Hcl | Amiodarone Hcl | 66 | 30 |
| Entresto | Sacubitril/Valsartan | 65 | 21 |
| Brilinta | Ticagrelor | 59 | 14 |
| Digoxin | Digoxin | 59 | 19 |
| Torsemide | Torsemide | 51 | 22 |
| Midodrine Hcl | Midodrine Hcl | 50 | 22 |
| Repatha Sureclick | Evolocumab | 50 | 16 |
| Chlorthalidone | Chlorthalidone | 48 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 19 |
| Ranolazine Er | Ranolazine | 39 | 18 |
| Farxiga | Dapagliflozin Propanediol | 38 | 14 |
| Nifedipine Er | Nifedipine | 36 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 35 | 17 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 32 | 19 |
| Atenolol | Atenolol | 30 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 29 | 14 |
| Sotalol | Sotalol Hcl | 28 | 11 |
| Cilostazol | Cilostazol | 27 | suppressed |
| Famotidine | Famotidine | 27 | 12 |
| Omeprazole | Omeprazole | 26 | 11 |
| Jardiance | Empagliflozin | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Simvastatin | Simvastatin | 24 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Jantoven | Warfarin Sodium | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Metformin Hcl | Metformin Hcl | 11 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 11 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,466.92 · 49 records | Abbott Laboratories | ACCOLADE SR, CARDIOMEMS, CARDIVA VASCADE MVP XL VVCS 10-12F, COREVALVE EVOLUT R, ELIQUIS, EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX, FLOWTRIEVER, FUROSCIX, General - Balloon Catheters, General - Brady, General - Tachy, General - Therapies, INGEVITY MRI, JARDIANCE, Kerendia, LINQ II, LUX-Dx Insertable Cardiac Monitor, LifeVest, MITRACLIP, NAVITOR, RESONATE EL ICD VR, SYMPLICITY G3, VYNDAQEL, Wolverine Coronary Cutting Balloon | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error